Doxa AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0005624756
SEK
0.49
0.03 (6.99%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company has declared negative results in Dec'2024 after 4 consecutive positive quarters

  • NET PROFIT(HY) At SEK -108.8 MM has Grown at -1,233.33%
  • OPERATING CASH FLOW(Y) Lowest at SEK -438 MM
  • INTEREST(HY) At SEK 37.6 MM has Grown at 149.01%
2

Risky -

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 694 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.60

stock-summary
Return on Equity

-24.95%

stock-summary
Price to Book

0.34

Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Jun 2025)
Net Profit:
-81 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.12%
0%
23.12%
6 Months
-18.2%
0%
-18.2%
1 Year
-61.71%
0%
-61.71%
2 Years
-86.8%
0%
-86.8%
3 Years
-90.33%
0%
-90.33%
4 Years
-83.16%
0%
-83.16%
5 Years
-60.04%
0%
-60.04%

Doxa AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.76%
EBIT Growth (5y)
-334.60%
EBIT to Interest (avg)
-1.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.59
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.77%
ROE (avg)
0.76%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.31
EV to EBIT
-4.85
EV to EBITDA
-5.49
EV to Capital Employed
0.60
EV to Sales
129.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-12.41%
ROE (Latest)
-22.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 252.00% vs 0.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -185.82% vs 96.65% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.80",
          "val2": "2.50",
          "chgp": "252.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.40",
          "val2": "-22.00",
          "chgp": "66.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "18.10",
          "val2": "19.50",
          "chgp": "-7.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-80.60",
          "val2": "-28.20",
          "chgp": "-185.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,965.90%",
          "val2": "-8,880.00%",
          "chgp": "191.41%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 56.57% vs 90.38% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -690.37% vs 831.58% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.50",
          "val2": "9.90",
          "chgp": "56.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-540.40",
          "val2": "-30.70",
          "chgp": "-1,660.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "22.50",
          "val2": "2.10",
          "chgp": "971.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,221.10",
          "val2": "302.10",
          "chgp": "-504.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,723.30",
          "val2": "291.90",
          "chgp": "-690.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-34,877.40%",
          "val2": "-3,303.00%",
          "chgp": "-3,157.44%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
8.80
2.50
252.00%
Operating Profit (PBDIT) excl Other Income
-7.40
-22.00
66.36%
Interest
18.10
19.50
-7.18%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-80.60
-28.20
-185.82%
Operating Profit Margin (Excl OI)
-6,965.90%
-8,880.00%
191.41%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 252.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -185.82% vs 96.65% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
15.50
9.90
56.57%
Operating Profit (PBDIT) excl Other Income
-540.40
-30.70
-1,660.26%
Interest
22.50
2.10
971.43%
Exceptional Items
-1,221.10
302.10
-504.20%
Consolidate Net Profit
-1,723.30
291.90
-690.37%
Operating Profit Margin (Excl OI)
-34,877.40%
-3,303.00%
-3,157.44%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 56.57% vs 90.38% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -690.37% vs 831.58% in Dec 2023

stock-summaryCompany CV
About Doxa AB stock-summary
stock-summary
Doxa AB
Pharmaceuticals & Biotechnology
Doxa AB is a Sweden-based company which develops products based on bio-active ceramics. The Company develops, manufactures and commercializes products based upon its technology platform of calcium aluminate hydrate and bioactive ceramics. Activities are divided into the therapy areas of orthopedics and odontology. Research areas within orthopedics are methods for treating fractures resulting from osteoporosis, reconstructive orthopedics and coating of implants. Research areas within odontology are tooth restoration and implant fixation.
Company Coordinates stock-summary
Company Details
Axel Johanssons Gata 4-6 , UPPSALA None : 754 50
stock-summary
Tel: 46 18 4782000
stock-summary
Registrar Details